BibliografiaTORNA INDIETRO
1. Bugbee AC, Coleman AE, Wang A et coll. Telmisartan treatment of refractory
proteinuria in a dog. J. Vet. Intern. Med. 2014;28(6):1871-1874.
2. Cianciolo RE, Brown CA, Mohr FC et coll. Pathologic evaluation of canine renal
biopsies: methods for identifying features that differentiate immune-mediated
glomerulonephritides from other categories of glomerular diseases. J. Vet. Intern.
Med. 2013;27(Suppl 1):S10-S18.
3. Harley L, Langston C. Proteinuria in dogs and cats. Can. Vet. J. 2012;53(6):631-636.
4. Inman AL, Allen-Durrance AE, Cianciolo RE et coll. Familial nephropathy in
Bracchi Italiani: 8 cases (2012-2019). J. Am. Vet. Med. Assoc. 2021;259(12):1422-1427.
5. IRIS Canine GN Study Group Diagnosis Subgroup, Littman MP, Daminet S
et coll. Consensus recommendations for the diagnostic investigation of dogs with
suspected glomerular disease. J. Vet. Intern. Med. 2013;27(Suppl 1):S19-S26.
6. IRIS Canine GN Study Group Established Pathology Subgroup, Segev G,
Cowgill LD et coll. Consensus recommendations for immunosuppressive treatment
of dogs with glomerular disease based on established pathology. J. Vet. Intern. Med.
2013;27(Suppl 1):S44-S54.
7. IRIS Canine GN Study Group Standard Therapy Subgroup, Brown S, Elliott J
et coll. Consensus recommandations for standard therapy of glomerular disease
in dogs. J. Vet. Intern. Med. 2013;27(Suppl 1):S27-S43.
8. Klosterman ES, Pressler BM. Nephrotic syndrome in dogs: clinical features
and evidence-based treatment considerations. Top. Companion Anim. Med.
2011;26(3):135-142.
9. Lees GE, Brown SA, Eliott J et coll. Assessment and management of proteinuria
in dogs and cats: 2004 ACVIM forum consensus statement (small animal).
J. Vet. Intern. Med. 2005;19(3):377-385.
10. Littman MP. Protein-losing nephropathy in small animals. Vet. Clin. North Am.
Small Anim. Pract. 2011;41(1):31-62.
11. Lourenço BN, Coleman AE, Brown SA et coll. Efficacy of telmisartan for the
treatment of persistent renal proteinuria in dogs: a double‐masked, randomized
clinical trial. J. Vet. Intern. Med. 2020;34(6):2478-2496.
12. Schneider SM, Cianciolo RE, Nabity MB et coll. Prevalence of immune-complex
glomerulonephritides in dogs biopsied for suspected glomerular disease:
501 cases (2007-2012). J. Vet. Intern. Med. 2013;27(Suppl 1):S67-S75.
13. Segev G, Cowgill LD, Jessen S et coll. Renal amyloidosis in dogs: a retrospective
study of 91 cases with comparison of the disease between Shar-Pei and
non-Shar-Pei dogs. J. Vet. Intern. Med. 2012;26(2):259-268.
14. White CR, Langston C, Hohenhaus AE et coll. Evaluation of the relationship
between clinical variables and thromboelastography findings in dogs with
protein-losing nephropathy. J. Vet. Emerg. Crit. Care (San Antonio).
2016;26(1):74-79.
Patologia comparata del tumore alla prostata del cane e dell'uomo
Sebbene relativamente raro nei cani, il cancro alla prostata (PCa) è il tumore non cutaneo più comune negli uomini. Le ghiandole prostatiche umane e canine condividono molte caratteristiche funzionali, anatomiche e fisiologiche. A causa di queste somiglianze, il PCa canino è stato proposto come modello per il PCa negli uomini.
